WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, debuted today with a ...
Entasis Therapeutics Holdings Inc. has described mannan-binding lectin serine protease 2 (MASP2) and/or mannan-binding lectin serine protease 3 (MASP3) inhibitors reported to be useful for the ...
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace. Here we go again. Entasis Therapeutics has been struggling in the public marketplace. There is certainly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback